- 1 Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC
- 2 WHO Clinical Characterisation Protocol UK Protocol: prospective observational study
- 3

4 Authors

- 5 Anna Maria Geretti^{*1}
- 6 Alexander J. Stockdale^{*1}
- 7 Sophie H. Kelly*¹
- 8 Muge Cevi k^2
- 9 Simon Collins³
- 10 Laura Waters^{4,5}
- 11 Giovanni Villa⁶
- 12 Annemarie Docherty^{7,8}
- 13 Ewen M Harrison⁷
- 14 Lance Turtle¹
- 15 Peter JM Openshaw⁹
- 16 J Kenneth Baillie^{8,10}
- 17 Caroline A. Sabin^{11,12}\$
- 18 Malcolm G Semple^{1,13}\$
- 19
- 20 *Joint first authors
- 21 \$ Joint senior authors
- 22
- 23 CHASE study group**
- ²⁴ **Daniel Bradshaw¹⁴, Alison Brown¹⁴, Nicky Connor¹⁴, Valerie Delpech¹⁴, Saye Khoo¹,
- 25 Tamyo Mbisa^{12, 14}, Chloe Orkin¹⁵, Ann Sullivan¹⁶.
- 26
- 27 ISARIC4C Investigators [Listed separately]
- 28

29 Affiliations

- 30 1. National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU)
- in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological
- 32 Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
- 2. Division of Infection and Global Health Research, School of Medicine, University of St
- 34 Andrews, St Andrews, UK

- 35 3. HIV i-Base, London, UK
- 36 4. Mortimer Market Centre, Central and North West London NHS Foundation Trust,
- 37 London, UK
- 38 5. British HIV Association
- 39 6. Department of Global Health and Infection, Brighton and Sussex Medical School,
- 40 University of Sussex, Brighton, UK
- 41 7. Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK
- 42 8. Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK
- 43 9. National Heart and Lung Institute, Imperial College London, London, UK
- 44 10. Roslin Institute, University of Edinburgh, Edinburgh, UK
- 45 11. University College London, London, UK
- 46 12. NIHR HPRU in Blood Borne and Sexually Transmitted Infections at UCL
- 47 13. Respiratory Medicine, Alder Hey Children's Hospital, Institute in The Park, University of
- 48 Liverpool, Alder Hey Children's Hospital, Liverpool, UK
- 49 14. Public Health England, London, UK
- 50 15. Bart's Health and Queen Mary University of London, London, UK
- 51 16. Chelsea and Westminster Hospital, London, UK
- 52
- 53 Correspondence
- 54 For queries related to people with HIV:
- 55 Prof Anna Maria Geretti, MD, PhD, FRCPath
- 56 Institute of Infection, University of Liverpool, 8 West Derby Street, Liverpool L69 7BE
- 57 Email: geretti@liverpool.ac.uk
- 58 Telephone: +44 151 795 9625
- 59

60 For queries related to the ISARIC CCP-UK study

- 61 Prof Malcolm G Semple, PhD, FRCPE, FRCPCH
- 62 Institute of Infection, University of Liverpool, 8 West Derby Street, Liverpool L69 7BE
- 63 Email: M.G.Semple@liverpool.ac.uk
- 64 Telephone: +44 795 833 5337
- 65
- 66 Author Contributions:

67 AMG - designed the study concept, reviewed all aspects of the data analysis and

68 interpretation, contributed to the writing of the manuscript, and performed the final review of

69 the manuscript.

- AJS performed the data analysis and contributed to the data interpretation and the writing of
- 71 the manuscript.
- 72 SHK performed the initial literature search and contributed to the data analysis and
- 73 interpretation and the writing of the manuscript.
- 74 MC contributed to conceptualisation and review of the manuscript
- 75 LW contributed to conceptualisation and review of the manuscript
- 76 SC contributed to conceptualisation and review of the manuscript
- 77 GV contributed to data analysis and interpretation and the writing of the manuscript
- AD contributed to the ISARIC CCP-UK study design and data collection and reviewed themanuscript
- 80 EMH contributed to the ISARIC-CCP UK study design and data collection and reviewed
- 81 the manuscript
- LT- contributed to the ISARIC-CCP UK study design and data collection and reviewed themanuscript
- 84 PJMO ISARIC CCP-UK Co-Lead investigator, sourced funding, contributed to the ISARIC
- 85 CCP-UK study design and data collection and reviewed the manuscript
- 36 JKB ISARIC CCP-UK Consortium lead investigator, sourced funding, contributed to the
- 87 ISARIC CCP-UK study design and data collection and reviewed the manuscript
- 88 CAS advised on all aspects of the conceptualisation and data analysis and interpretation,
- and contributed to the writing and final review of the manuscript
- 90 MGS ISARIC CCP-UK Protocol Chief Investigator and guarantor of the data, sourced
- 91 permissions and funding, contributed to the ISARIC CCP-UK study design and data
- 92 collection and reviewed the manuscript.

93 ABSTRACT

94 Background. There is conflicting evidence about how HIV infection influences COVID-19.

95 We compared the presentation characteristics and outcomes of people with and without HIV

96 hospitalised with COVID-19 at 207 centres across the United Kingdom.

97 Methods. We analysed data from people with laboratory confirmed or highly likely COVID-98 19 enrolled into the ISARIC CCP-UK study. The primary endpoint was day-28 mortality 99 after presentation. We used Kaplan-Meier methods and Cox regression to describe the 100 association with HIV status after adjustment for sex, ethnicity, age, indeterminate/probable 101 hospital acquisition of COVID-19 (definite hospital acquisition excluded), presentation date, 102 and presence/absence of ten comorbidities. We additionally adjusted for disease severity at 103 presentation as defined by hypoxia/oxygen therapy.

104 Findings. Among 47,539 patients, 115 (0.24%) had confirmed HIV-positive status and 105 103/115 (89.6%) had a record of antiretroviral therapy. At presentation, relative to the HIV-106 negative group, HIV-positive people were younger (median 55 versus 74 years; p<0.001), 107 had a higher prevalence of obesity and moderate/severe liver disease, higher lymphocyte 108 counts and C-reactive protein, and more systemic symptoms. The cumulative incidence of 109 day-28 mortality was 25.2% in the HIV-positive group versus 32.1% in the HIV-negative 110 group (p=0.12); however, stratification for age revealed a higher mortality among HIV-111 positive people aged below 60 years. The effect of HIV-positive status was confirmed in 112 adjusted analyses (adjusted hazard ratio [HR] 1.49, 95% confidence interval [CI] 0.99-2.25; 113 p=0.06). Following additional adjustment for disease severity at presentation, mortality was 114 higher in HIV-positive people (adjusted HR 1.63; 95% CI 1.07-2.48; p=0.02). In the HIV-115 positive group, mortality was more common among those who were slightly older and among 116 people with obesity and diabetes with complications. 117 Interpretation. HIV-positive status may be associated with an increased risk of day-28

118 mortality following a COVID-19 related hospitalisation.

119 Funding. NIHR, MRC, Wellcome Trust, Department for International Development, Bill and

- 120 Melinda Gates Foundation.
- 121 Study registration ISRCTN66726260

123 RESEARCH IN CONTEXT

124 Evidence before this study

We searched PubMed for articles in all languages containing the words "COVID*", 125 "coronavirus", "SARS CoV-2" AND "HIV". After screening on 23rd July 2020, we found 51 126 articles reporting outcomes of COVID-19 in HIV-positive people. Of these, 2 were 127 128 systematic reviews, 24 were single case reports or case series of under 10 participants, and 12 129 were larger case series or retrospective cohorts without matched controls. There were two 130 cohort studies that matched HIV-positive people diagnosed with COVID-19 to the general 131 population attending for HIV care in the same area, and three studies that matched HIV-132 positive people diagnosed with COVID-19 to HIV-negative controls. Some of the evidence 133 from the United States and Europe to date suggests that people with HIV experience a similar 134 disease course and outcomes of COVID-19 compared to the general population. However, 135 many of the studies are limited by small sample size, lack of comparator group and lack of 136 adjustment for potential confounding. In contrast, preliminary results from a cohort study of over 20,000 participants in South Africa indicate that HIV-positive status more than doubles 137 138 the risk of COVID-19 related mortality. Currently, the evidence from the United Kingdom is 139 limited to two case series comprising a total of 21 patients.

140

141 Added value of this study

142 This study analysed data collected from 207 sites across the United Kingdom as part of 143 ISARIC CCP, the largest prospective cohort of patients hospitalised with COVID-19, to 144 evaluate the association between HIV-positive status and day-28 mortality. The study has the 145 benefit of a relatively large number of participants with HIV (n=115, almost all receiving 146 antiretroviral therapy) and importantly, the ability to direct compare their presenting 147 characteristics and outcomes to those of 47,424 HIV-negative controls within the same 148 dataset. This includes the ability to assess the influence of gender, ethnicity and age, as well 149 as the effect of key comorbidities including chronic cardiac, pulmonary, renal and 150 haematological disease, diabetes, obesity, chronic neurological disorder, dementia, liver 151 disease, and malignancy. Unlike some of the other evidence to date, but in line with the data 152 from South Africa, this study indicates that HIV-positive status may increase the risk of 153 mortality with COVID-19 compared to the general population, with an effect that was 154 especially evident among people with HIV aged below 60 years and was independent of 155 gender or ethnicity. Although we detected an association between mortality among people

- 156 with HIV and occurrence of obesity and diabetes with complication, the effect of HIV-
- 157 positive status persisted after adjusting for comorbidities.
- 158

159 **Implications of all the available evidence**

160 People with HIV may be at increased risk of severe outcomes from COVID-19 compared to

161 the general population. Ongoing data collection is needed to confirm this association.

162 Linkage of hospital outcome data to the HIV history will be paramount to establishing the

163 determinants of the increased risk. COVID-19 related hospitalisation should pursue

systematic recording of HIV status to ensure optimal management and gathering of evidence.

166 Introduction

167 Factors associated with COVID-19 related mortality include older age and presence of 168 chronic comorbidities, particularly obesity, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), serious cardiovascular disease, type II diabetes, and 169 transplant-related immunosuppression.¹⁻⁵ There is no conclusive evidence about the 170 relationship with HIV infection. If untreated, HIV causes progressive immunosuppression; 171 172 however, antiretroviral therapy (ART) restores immune function and life-expectancy.⁶ Immune restoration is not always complete despite effective ART, however, and a subset of 173 174 people with HIV (PWH) remains at risk of persistent immune dysfunction,⁷ which might augment severity of COVID-19, or conversely, possibly reduce the immune responses that 175 can complicate COVID-19.⁸ Although some antiretroviral drugs have been proposed to 176 protect against COVID-19, the evidence remains uncertain.^{9,10} Importantly, HIV might 177 increase the risk of adverse COVID-19 outcomes due to the common prevalence of co-factors 178 such as CKD, COPD, and diabetes,¹¹ alongside socioeconomic variables that may carry a 179 negative influence.¹² 180

181

182 Several case series and observational cohort studies have described the outcomes of COVID-19 in PWH across Europe,^{9,13-19} Asia,^{18,19} and the United States.^{8,18-22} These studies have 183 184 often been limited by small sample size, lack of direct comparative data from people without 185 HIV, or inability to adjust for comorbidities. Some reports from Italy and New York indicated that HIV did not increase the risk of COVID-19 related hospitalisation or 186 mortality,^{4,14,21} whereas two others suggested an increased risk of mortality among PWH 187 hospitalised with COVID-19.9,20 Preliminary data from South Africa similarly suggest that 188 189 HIV-positive status more than doubled the risk of COVID-19 related mortality.²³

190

191 To characterise the presenting characteristics and outcomes of COVID-19 related 192 hospitalisation in PWH relative to those without HIV in the United Kingdom (UK), we 193 analysed data collected within the International Severe Acute Respiratory and emerging 194 Infections Consortium (ISARIC) Clinical Characterisation Protocol (CCP), the largest 195 prospective observational study of patients admitted to hospital with COVID-19 worldwide.²⁴ 196

197 Methods

198 Study design

ISARIC CCP-UK is an ongoing prospective cohort study in acute care hospitals in England, 199 Scotland, and Wales.²⁴ The protocol, case report form (CRF, version 9.2) and other study 200 201 materials, and details of the Independent Data and Material Access Committee are available online.²⁴ The study was activated in the UK on 17th January 2020. Inclusion criteria were 202 203 people aged ≥ 18 years who were admitted to one of the participating acute care trusts (207 at 204 the time of data extraction) with either laboratory-confirmed or highly likely (based on 205 clinical, laboratory and radiological findings) SARS CoV-2 infection. PCR-based virus 206 detection in nasopharyngeal swabs was the only test available during the study and the 207 decision to test was at the discretion of the attending clinical team, who also decided upon 208 hospital admission, transfer into critical care and use of ventilation. For the present analyses, 209 baseline was defined as the date of hospital admission or symptom onset (for those with 210 symptom onset after hospitalisation, see below). Our analyses included individuals with a baseline date that was on or before 4^{th} June 2020 for whom ≥ 14 days had elapsed until the 211 date of data extraction on 18th June 2020. Individuals without information on the date of 212 admission or with a baseline date after 4th June 2020 were excluded. Where the date of 213 214 symptom onset was missing, we assumed that symptoms began on the date of the SARS-215 COV-2 PCR test, or if this was not recorded, the date of admission. Information on positive 216 HIV status, as reported to ISARIC CCP-UK, was confirmed through cross-checking with 217 reported receipt of ART (n=103), receipt of *Pneumocystis jirovecii* prophylaxis in the 218 absence of non-HIV indications (n=2), or directly with a site investigator (n=10). Individuals 219 with missing HIV status and those with unconfirmed HIV-positive status were excluded from 220 the analyses.

221

222 Statistical analysis

223 Presenting characteristics were compared between HIV-positive and HIV-negative people 224 and between PWH who died and those who survived to discharge using Wilcoxon rank sum 225 tests (for continuous variables) and Pearson's chi-squared or Fisher's exact test (for 226 categorical variables). For all individuals, follow-up ended on the date of death. Patients 227 discharged to receive palliative care in the community were considered to have died three 228 days following discharge. Follow-up was right censored at day 28 for those remaining alive 229 as an inpatient, or for those who were discharged not for palliative care prior to day 28. A 230 data check showed that the vast majority of those discharged prior to day 28 were still alive

231 on this date. Follow-up on patients transferred to another facility was censored on the date of 232 transfer. For patients who died, were transferred or discharged on the date of admission or 233 who had no further follow-up recorded beyond the first day, we recorded 0.5 days of follow-234 up time. The primary analysis used a Kaplan-Meier approach to visually display the 235 cumulative incidence of mortality over this period, overall and in strata defined by sex and 236 age. Cox proportional hazards regression with the Efron method for ties was then used to 237 describe the association of mortality with HIV status, before and after adjustment for the 238 confounders: following potential sex, ethnicity, age (in quadratic form). 239 indeterminate/probable hospital acquisition of COVID-19 (as defined above), and ten 240 comorbidities at admission (a series of binary variables to indicate the presence or absence of 241 each of chronic cardiac disease, chronic pulmonary disease, chronic renal disease, diabetes, 242 obesity, chronic neurological disorder, dementia, liver disease [mild, moderate or severe], 243 malignancy, and chronic haematological disease). We also included adjustment for the 244 baseline date to account for changes in mortality over the period of interest. Where entries on 245 comorbidity (presence or absence) were partially missing from the study CRF, we assumed 246 that missing data indicated the absence of the specific comorbidity; however, participants 247 with missing entries on all comorbidities were excluded from these adjusted analyses. 248 Finally, we fitted a further model with additional adjustment for hypoxia at presentation, 249 defined as oxygen saturation (SpO2) <94% on air or a record of receiving oxygen, as a 250 marker of presenting disease severity, in order to assess whether any increased/decreased risk 251 of mortality in PWH could be explained by a different stage of disease advancement at 252 hospitalisation. A series of sensitivity analyses were performed for the main mortality 253 outcome: i) we repeated the analyses after censoring follow-up on the day of discharge for 254 those discharged before day 28; ii) we included those with definite hospital-acquired COVID-255 19 (baseline = date of symptom onset); iii) we used symptom onset date as the baseline date 256 for all (rather than admission date where applicable); iv) we excluded PWH lacking a record 257 of ART; v) we calculated propensity scores for HIV-positive status using a logistic regression 258 model based on sex, ethnicity, age (in quadratic form), indeterminate/probable hospital 259 acquisition of COVID-19, smoking status, baseline date, and ten comorbidities, and included 260 the propensity score in a Cox regression model for death at 28 days; and vi) we considered a 261 binary endpoint of 14-day mortality and performed logistic regression (with the same 262 confounder adjustment as described above). In the HIV-positive group, we used a Cox 263 proportional hazard model to investigate the associations of presenting characteristics with

day-28 mortality. Analyses were conducted in Stata v16·1 (Statcorp, College Station, TX,

265 USA).

266

267

268 **Results**

269 **Participants**

ISARIC CCP-UK recorded 53,992 people with COVID-19 between 17th January 2020 and 270 271 18th June 2020. After excluding non-eligible participants (Figure 1), the final analysis 272 included 47,539 patients, of whom 115 (0.24%) had confirmed HIV-positive status. The 273 characteristics of patients excluded from the analysis did not differ by sex, ethnicity or age; in 274 particular, the characteristics of those excluded due to missing data on HIV status closely 275 resembled those reported to be HIV-negative (Supplementary Table 1). Among PWH, one 276 person was diagnosed with HIV during the admission and 103 (89.6%) had an ART record. 277 The regional distribution of study participants with HIV compared to the total UK population 278 of people accessing HIV care (2018 data) is shown in Supplementary Table 2.

279

280 Characteristics at presentation

281 The presenting characteristics according to HIV status are summarized in Tables 1-3 and 282 Figure 2. PWH were younger than HIV-negative people (medians of 55 versus 74 years, 283 p<0.001) (Table 1, Figure 2). There were fewer women in the HIV-positive group but 284 significantly larger proportions of people of black ethnicity. A similar proportion had no 285 recorded comorbidities, whereas occurrence of ≥ 2 comorbidities was more prevalent in the 286 HIV-negative group. PWH had lower prevalence of chronic cardiac disease, chronic 287 pulmonary disease, chronic neurological disorders, dementia, malignancy and 288 rheumatological disease, and higher rates of obesity and moderate/severe liver disease. There 289 were small differences in the prevalence of asthma, diabetes without complications, mild 290 liver disease, and malnutrition, whereas proportions with CKD, diabetes with complications 291 and chronic haematological disease were similar in the two groups.

292

The duration of symptoms was longer in the HIV-positive group (medians of 5 vs. 3 days, p=0.001) (Table 2). PWH were more likely to present with systemic symptoms and signs, including fever, headache, myalgia and tachycardia, and to have cough, sore throat and chest pain. To a lesser extent, they also had more common occurrence of gastrointestinal symptoms. Respiratory rate, occurrence of tachypnoea and hypoxia, and radiological

evidence of chest infiltrates did not show significant differences between the two groups.
PWH presented with lower total white blood cell and platelet count, but higher lymphocyte
count and C-reactive protein (CRP) (Table 3). Other laboratory parameters showed no
significant differences.

302

303 COVID-19 outcomes

During admission, whereas there was no significant difference in the proportion of participants who received oxygen between the two groups, significantly higher proportions of PWH were admitted to critical care and received non-invasive and invasive ventilation (Figure 3). However, after adjustment for sex, ethnicity, age, baseline date, indeterminate/probable hospital acquisition of COVID-19, and ten comorbidities, the odds of admission to critical care were similar between the two groups (odds ratio [OR] 1.13; 95% confidence interval [CI] 0.72-1.75; p=0.59) (Supplementary Table 3).

311

Overall, by day 28, 13,981 (29.4%) participants were known to have died, 23,642 (49.7%) 312 313 had been discharged alive, 3,715 (7.8%) remained in hospital, and 1,801 (3.8%) had 314 transferred to other facilities; in the remaining 4,400 (9.2%) the outcome was unknown 315 (Supplementary Table 4). In the HIV-positive group, 26 (22.6%) were known to have died compared to 13,955 (29.1%) of the HIV-negative group; the cumulative incidence of day-28 316 317 mortality was $25 \cdot 2\%$ vs. $32 \cdot 1\%$, respectively (p=0.12, log-rank test, Figure 4 A). Whilst findings were similar (in unadjusted analyses) regardless of sex (Figure 4 B, C), stratification 318 319 for age revealed higher mortality among PWH in the two younger age groups (<50 years and 320 50-59 years) but not in those aged 60-79 years (Figure 3 D-F).

321

322 In unadjusted models (Table 4), the cumulative hazard of day-28 mortality was 26% lower in 323 HIV-positive vs. HIV-negative people (HR 0.74, 95% CI 0.50-1.08; p=0.12). The hazard was 324 similar after adjustment for either sex or ethnicity; in contrast, and as expected based on the 325 stratified Kaplan-Meier analyses, adjustment for age resulted in a change in the direction of 326 the association (adjusted HR 1.39, 95% CI 0.94-2.09; p=0.10) (Table 4). After further adjustment for sex, ethnicity, age, baseline date, indeterminate/probable hospital acquisition 327 328 of COVID-19 and ten co-morbidities, the risk of mortality was 49% higher in PWH (adjusted 329 HR 1.49; 95% CI 0.99-2.26; p=0.06). Following additional adjustment for disease severity at 330 presentation (based on a record of hypoxia or oxygen therapy), the risk of mortality was 63% 331 higher in PWH (adjusted HR 1.63; 95% CI 1.07- 2.48; p=0.02) (Table 4). After day 28, there

were no deaths recorded in the HIV-positive group whereas 586 deaths occurred in the HIV-negative group.

334

Sensitivity analyses showed consistent results (Supplementary Table 5). In particular, censoring follow-up on the day of discharge for those discharged before day 28, including patients with definite hospital acquired COVID-19, using symptom onset as the start of follow-up, or excluding PWH lacking an ART record did not significantly alter the model. A separate logistic regression model with a binary variable of day-14 mortality showed increased odds of mortality in the HIV-positive group (adjusted OR 1.77; 95% CI 1.06-2.95; p=0.03).

342

In the HIV-positive group, relative to patients who survived by day 28, patients who died were slightly older and had a higher prevalence of obesity and diabetes with complications (Table 5 and Supplementary Tables 6 and 7). An ART record was more often missing among those who died. No indications of other major differences were observed.

347

348 Discussion

349 Principal findings

350 In this study of 115 HIV-positive and 47,979 HIV-negative people, we found evidence 351 suggesting a 63% increased risk of day-28 mortality among PWH hospitalised with COVID-352 19 compared to HIV-negative individuals in the same dataset, after adjustment for sex, 353 ethnicity, age, baseline date, ten key comorbidities, and disease severity at presentation (as 354 indicated by a record of hypoxia or receiving oxygen therapy). The latter adjustment took 355 into consideration that doctors may be more likely to admit HIV-positive people with 356 COVID-19 despite less severe symptoms. A striking difference in mortality was seen in the 357 younger age groups (<50 years and 50-59 years), although the number of older PWH was 358 small.

359

The role of age, sex and ethnicity on COVID-19 outcomes is the focus of much research.^{1,2,25} PWH in our study were significantly younger than the HIV-negative group and adjusting for age changed the direction of the association between HIV status and day-28 mortality, suggesting that age was a significant confounder in our analyses. Men were more prevalent in the HIV-positive group, which is consistent with the epidemiology of HIV infection in the UK, where men represent just over two thirds of the whole population with HIV.²⁶ People of

black ethnicity made up nearly 42% of the HIV-positive group, whereas men and women of
black African ethnicity account for ~26% of the total number of PWH in the UK.²⁶
Nonetheless, adjustment for sex or ethnicity alone did not impact our relative hazard
estimates.

370

371 Whilst there is a recognised interplay between HIV and comorbidities, omitting the 372 adjustment for comorbidities did not modify the association. PWH had fewer comorbidities, 373 notably lower prevalence of chronic pulmonary disease and malignancies, and this is likely to 374 be partly a function of their younger age. HIV-positive people who died were older and were 375 more likely to suffer from obesity and diabetes with complications than those who survived to discharge. Similar trends have been seen in the general population.^{1,25} While these 376 377 observations highlight the importance of obesity and diabetes as cofactors, adjustment for 378 comorbidities in our model did not modify the association, suggesting that the apparent 379 increased risk of COVID-19 related mortality in PWH was not merely due to the presence of 380 promoting comorbidities.

381

382 *Comparison with other studies*

383 Evidence from published studies is not entirely consistent about the interplay between HIV and COVID-19.^{8,9,13-23} A case-control study from New York compared 88 PWH, all of whom 384 were receiving ART, and 405 HIV-negative controls matched by age, gender, ethnicity, and 385 calendar week of infection.²¹ The study found no difference in the outcomes of COVID-19 386 related hospitalisation after adjusting for demographics, COPD, smoking, and baseline 387 388 ferritin and white blood cell count. Apart from the differences in the study design and 389 geography, there are fundamental differences between our study population and the New York cohort described by Sigel et al.²¹ Most importantly, participants in the latter study were 390 older, with a median age of 61 years (IQR 54-67 years), whereas we found that the excess 391 392 mortality occurred in HIV-positive people aged below 60 years. Whereas malignancies were 393 recorded less commonly (3% vs. 10%), prevalence of obesity was nearly double in our cohort 394 (18% vs. 11%). At the other spectrum, preliminary data from the Western Cape Department 395 of Health in South Africa indicate that HIV-positive status was associated with increased hazard of mortality [adjusted HR 2.75].²³ Although the South African model did not account 396 for history of tuberculosis, obesity and socioeconomic status, it is of significance that HIV 397 398 suppression on ART made no difference to the risk.

400 *Strengths and limitations of this study*

401 A key strength of our study is the ability to perform a direct comparison of people with and 402 without HIV in the same dataset. Our analysis does not address risk factors for a COVID-19 403 diagnosis or a COVID-19 related hospitalisation among PWH, and cannot add to the current debate about the role of certain antiretroviral agents in modulating such risks.^{9,10} In addition, 404 due to the format of data collection in ISARIC CCP-UK, our analysis cannot provide 405 406 evidence of the role of HIV-related parameters on outcomes of COVID-19 related 407 hospitalisation, as we did not have details of the ART history, current and nadir CD4 cell 408 count, plasma HIV-1 RNA load, and history of previous HIV-related disease. Only a subset 409 of CRFs from participants with HIV included a record of receiving ART and the records were 410 frequently incomplete.

411

412 Numerically, HIV-positive people who died were more likely not to have a record of being 413 on ART than those who remained alive at day 28. However, it cannot be stated with certainty 414 that those lacking an ART record were untreated nor therefore that lack of ART played a role 415 in the adverse outcomes. Our experience of working with large HIV datasets is that we often 416 find that people with missing data have worse mortality outcomes, simply because mortality 417 prevents collection of a detailed treatment history. In the UK, 93% of the 103,000 people 418 estimated to have HIV infection have been diagnosed and of these the vast majority (97%) receives ART and maintains excellent suppression of the infection.²⁶ Among those with a 419 HIV diagnosis, only a small subset of $\sim 3\%$ is either not engaged with care or experiences 420 problems with virological control despite ART.²⁶ This suggests that the likelihood of PWH in 421 422 our study being off ART despite an absent record was overall low.

423

424 It is currently unclear how HIV infection and associated immune dysfunction modulates 425 infection with SARS CoV-2. Whilst immunosuppression was associated with poor COVID-19 outcomes in a recent meta-analysis,⁵ effective ART leads to immune reconstitution with 426 improved or normalised CD4 cell counts.⁶ We found no evidence of increased lymphopenia 427 428 among PWH in our study. Furthermore, compared to HIV-negative people, PWH were more 429 likely to experience systemic symptoms with fever and also showed higher CRP levels. These observations are likely to be reflective of the younger age of PWH in our study,²⁷ and at the 430 431 same time indicate preserved inflammatory responses in this group. This suggests that the 432 likelihood of PWH in our study being severely immunosuppressed was overall low.

434 *Conclusions and policy Implications*

435 After careful considerations and multiple adjustments for demographics, comorbidities and 436 disease severity on admission, our initial analyses of the outcomes of patients hospitalised 437 with COVID-19 in the UK show a signal towards an increased risk of day-28 mortality due to 438 HIV-positive status. The data for this study were collected during the peak of the UK 439 COVID-19 epidemic and the analysis contains a significant proportion of missing data, 440 including a high number of patients with missing HIV status, who were excluded from the 441 analysis. As the pandemic continues to spread in areas of increased HIV prevalence, our 442 observations highlight the importance of recording the HIV status of people hospitalised with 443 COVID-19 to ensure appropriate management during hospitalisation and gather further data 444 to improve our understanding of the reciprocal interactions between SARS-CoV-2 and HIV.

445

Despite effective ART and normalised CD4 cell counts, a subset of PWH continue to 446 experience immune activation, inflammation and a pro-coagulatory state,⁷ which may be 447 postulated to modulate the risk of COVID-19 related morbidity and mortality.^{28,29} One 448 449 determinant of such persistent immune dysfunction is the degree of immunosuppression 450 experienced prior to the start of ART, defined by a low nadir CD4 cell count and inverted CD4:CD8 ratio. In the UK, 43% of people newly diagnosed with HIV in 2018 had a CD4 451 count <350 cells/mm³, a threshold indicative of significant immunosuppression.²⁶ 452 453 Furthermore, current guidelines about starting ART immediately at the time to diagnosis 454 were implemented relatively recently, whereas in the past ART initiation was deferred until 455 the CD4 count had declined below thresholds of initially 200, then 350 and subsequently 500 cells cells/mm^{3,6,30} Thus, many PWH in the UK and worldwide will have experienced years 456 of uncontrolled HIV replication prior to commencing treatment, and may have experienced 457 458 earlier regimens of suboptimal efficacy, with lasting effects on immune function. Planned 459 linkage of the hospital dataset with the HIV clinic records will be required to clarify the role 460 of ART history, current and nadir CD4 cell count, plasma HIV-1 RNA load and previous 461 history of HIV-related disease on the outcomes observed in this study. Meanwhile, emphasis for PWH should be placed on early HIV diagnosis, prompt ART initiation, and optimised 462 463 screening for and control of comorbidities including obesity and diabetes.

Characteristic		HIV-posi	tive	HIV-negative		P-value
		n=115		n=47,424		
Age, median ye		55	(49, 61)	74	(60, 84)	< 0.001
Age group,	<40	7/113	(6.2)	2,574/46,882	(5.5)	< 0.001
n (%)	40-49	26/113	(23.0)	3,242/46,882	(6.9)	
	50-59	47/113	(41.6)	5,940/46,882	(12.7)	
	60-69	23/113	(20.4)	7,266/46,882	(15.5)	
	≥ 70	10/113	(8.9)	27,860/46,882	(59.4)	
Female, n (%)		39/114	(34.2)	20,280/47,258	(42.9)	0.06
Ethnicity,	White	44/106	(41.5)	35,501/42,163	(84.2)	< 0.001
n (%)	Black	48/106	(45.3)	1,473/42,163	(3.5)	
	Asian	1/106	(0.9)	2,247/42,163	(5.3)	
	Other	13/106	(12.3)	2,942/42,163	(7.0)	
Smoking,	Never	62/89	(69.7)	17,380/30,348	(57.3)	0.002
n (%)	Former	16/89	(18.0)	10,632/30,348	(35.0)	
	Current	11/89	(12.4)	2,336/30,348	(7.7)	
Comorbidities,	median number (IQR)	1	(0, 2)	2	(1, 3)	< 0.001
Comorbidities,	None	30/115	(26.1)	9,675/46,696	(20.7)	0.002
n (%)	1	44/115	(38.3)	13,532/46,696	(29.0)	
	2	29/115	(25.2)	11,518/46,696	(25.2)	
	≥3	12/115	(10.4)	11,971/46,696	(25.6)	
Type of	Chronic cardiac disease	20/111	(18.0)	14,603/45,008	(32.5)	0.001
comorbidities,	Chronic pulmonary disease ^a	12/114	(10.5)	8,048/44,872	(17.9)	0.04
n (%)	Asthma	11/110	(10.0)	6,228/44,712	(13.9)	0.23
	Chronic renal disease	19/110	(17.3)	7,861/44,683	(17.6)	0.93
	Diabetes, no complications	16/110	(14.6)	7,776/43,818	(17.8)	0.38
	Diabetes, with complications	8/110	(7.3)	3,300/43,543	(7.6)	0.90
	Obesity	19/105	(18.1)	4,588/40,419	(11.4)	0.03
	Chronic neurological disorder	7/110	(6.4)	5,579/44,432	(12.6)	0.05
	Dementia	3/111	(2.7)	7,458/44,508	(16.8)	< 0.001
	Mild liver disease	3/111	(2.7)	631/44,183	(1.4)	0.21
	Moderate/severe liver disease	6/111	(5.4)	858/43,378	(1.9)	0.008
	Malignancy	3/111	(2.7)	4,586/44,314	(10.4)	0.004
	Chronic haematological disease	4/111	(3.6)	1,923/44,266	(4.3)	1.0
	Rheumatological disease	6/111	(5.4)	4,867/44,138	(11.0)	0.06
	Malnutrition	5/105	(4.8)	1,129/41,811	(2.7)	0.21

465	Table 1. Summary of participant characteristics, stratified by HIV status
-----	---

466 ^aExcludes asthma. Abbreviations: IQR, Interquartile range.

Symptoms and Observations		HIV-positive		HIV-negative	P-value	
		n=115		n=47,424		
Presenting	Fever	94/114	(82.5)	30,623/47,039	(65.1)	< 0.001
symptoms,	Myalgia	26/96	(27.1)	6,349/34,806	(18.2)	0.03
n (%)	Headache	18/89	(20.2)	3,660/34,762	(10.5)	0.003
	Cough	88/114	(77.2)	30,997/47,031	(65.9)	0.01
	Dyspnoea	84/114	(73.7)	32,108/46,997	(68.3)	0.22
	Chest pain	24/101	(23.8)	5,221/38,269	(13.6)	0.003
	Sore throat	13/92	(14.1)	2,803/34,265	(8.2)	0.04
	Wheeze	5/94	(5.3)	3,289/36,209	(9.1)	0.28
	Rhinorrhoea	3/89	(3.4)	831/33,533	(2.5)	0.49
	Diarrhoea	25/100	(25.0)	7,271/39,305	(18.5)	0.10
	Nausea or vomiting	23/97	(23.7)	7,641/39,527	(19.3)	0.28
	Abdominal pain	13/96	(13.5)	4,026/38,105	(10.6)	0.34
	Fatigue	40/90	(44.4)	16,098/37,169	(43.3)	0.83
	Asymptomatic	0/115	(0)	887/47,424	(1.9)	0.28
Symptom	Systemic	103/114	` '	32,239/47,073	· /	< 0.00
group ^a ,	Respiratory	100/114	· /	38,697/47,112	· /	0.12
n (%)	Gastrointestinal	42/103	(40.8)	13,431/41,275		0.08
	uration, median days (IQR)	5	(1,9)	3	(0, 7)	0.001
Symptom	<3 days	108/115		41,247/47,055	· /	0.13
duration ^b ,	3-7 days	1/115	(0.9)	1,484/47,055	(3.2)	
n (%)	8-14 days	4/115	(3.5)	1,602/47,055	(3.4)	
	>14 days	2/115	(1.7)	2,722/47,055	(5.8)	
Presenting	Temperature, median °C (IQR)	37.8	(37.0, 38.6)		(36.6, 38.1)	
signs	Fever ≥37.8 °C, n (%)	59/111	(53.2)	16,432/45,414	(36.2)	< 0.00
	HR, median beats/min (IQR)	97	(82, 110)	90	(78, 105)	0.002
	Tachycardia ^c , n (%)	51/112	(45.5)	15,064/45,387	(33.2)	0.006
	RR, median breaths/min (IQR)	20	(18, 27)	21	(18, 26)	0.71
	Tachypnoea ^d , n (%)	50/107	(46.7)	23,284/45,165	(51.6)	0.32
	Hypoxia ^e /on oxygen, n (%)	50/108	(46.3)	23,948/45,199		0.16
	Infiltrates visible on CXR, n (%)	46/70	(65.7)	19,047/30,536	(62.4)	0.57
	Systolic BP, median mmHg (IQR)	130	(117, 143)	130	(114, 147)	0.90
	Diastolic BP, median mmHg (IQR)	80	(68, 88)	74	(65, 84)	0.009

468 **Table 2.** Presenting symptoms and observations, stratified by HIV status

469 ^aSystemic symptoms: ≥ 1 of fever, myalgia or headache; Respiratory symptoms: ≥ 1 of cough, dyspnoea, 470 chest pain, sore throat, wheeze; Gastrointestinal symptoms: ≥ 1 of: Diarrhoea, nausea, vomiting or 471 abdominal pain. ^bBased on the onset of symptoms relative to the date of admission, COVID-19 472 acquisition was classed as community (<3 days), indeterminate (3-7 days), probable hospital (8-14 days), and definite hospital (>14 days). ^cDefined as HR >100 beats/min. ^dDefined as RR >20 breaths/min. 473 474 ^eDefined as SpO2 <94% on air; proportions with SpO2 <94% or on oxygen therapy at presentation were 475 30/108 (27.8%) and 32/105 (30.5%) respectively in the HIV-positive group, and 14,463/45,123 (32.1%) 476 and 14,203/44,093 (32.2%) in the HIV-negative group. Abbreviations: IQR, Interquartile range; HR, 477 Heart rate; RR, Respiratory rate; CXR, Chest X-ray; BP, Blood pressure.

Laboratory parameter		HIV posi	tive	HIV-negative		P-value
		n=115		n=47,424		
Haemoglobin, median g/L	(IQR)	129	(116, 144)	129	(113, 143)	0.77
Anaemia ^a , n (%)		37/101	(36.6)	15,549/40,450	(38.8)	0.65
WBC, median count x10 ⁹ /	L (IQR)	6.6	(4.9, 9.0)	7.4	(5.4, 10.4)	0.01
Lymphocytes, median cou	nt $x10^9/L$ (IQR)	1.0	(0.8, 1.5)	0.9	(0.6, 1.3)	< 0.001
Lymphopenia ^b , n (%)		47/102	(46.1)	22,991/39,719	(57.9)	0.02
Platelets, median count x1	$0^{6}/L$ (IQR)	200	(150, 263)	217	(164, 285)	0.04
Thrombocytopenia ^c , n (%)		24/99	(24.2)	7,431/39,698	(18.7)	0.16
Prothrombin time, median	sec (IQR)	13.6	(11.0, 15.0)	13.2	(11.8.15.0)	0.71
Creatinine, median µmol/l	L (IQR)	89	(72, 134)	86	(67, 121)	0.21
eGFR ^d , median ml/min/1.	$73m^2$ (IQR)	76	(52, 101)	73	(48, 97)	0.30
eGFR ml/min/1.73m ² ,	≥ 60	67/95	(70.5)	24,758/38,782	(63.8)	0.15
n (%)	30-59	18/95	(19.0)	9,774/38,782	(25.2)	
	<30	10/95	(10.5)	4,250/38,782	(11.0)	
	15-29	4/95	(4.2)	2,844/38,782	(7.3)	
	<15	6/95	(6.3)	1,406/38,782	(3.6)	
ALT, median U/L (IQR)		27	(19, 44)	26	(17, 43)	0.28
ALT >40 U/L, n (%)		26/85	(30.6)	8,452/30,443	(27.8)	0.56
Glucose, median mmol/L	(QR)	6.7	(5.8, 9.8)	6.8	(5.8, 8.9)	0.63
Hyperglycaemia ^e , n (%)		10/52	(19.2)	2,900/19,522	(14.9)	0.38
C-reactive protein, mediar	mg/L (IQR)	110	(51, 200)	83	(36, 157)	0.02

479 **Table 3.** Presenting laboratory parameters, stratified by HIV status

480 ^aDefined as haemoglobin <130 g/L in males and <115 g/L in females. ^bDefined as lymphocyte count 481 <1.0 $\times 10^9$ /L. ^cDefined as platelet count <150 $\times 10^6$ /L. ^dBased on the Modification of Diet in Renal 482 Disease (MDRD) formula where eGFR (mL/min/1.73 m²) = 175 × (Scr/88.4)-1.154 × (Age)-0.203 × 483 (0.742 if female) × (1.212 if Black ethnicity). ^cDefined as glucose >11 mmol/L. Abbreviations: IQR, 484 Interquartile range; Abbreviations: IQR, Interquartile range; WBC, White blood cells; eGFR, 485 estimated glomerular filtration rate; ALT, alanine transaminase.

487	Table 4. Cox	proportional hazard	ls model of the a	ssociation between	HIV status and day-28
-----	--------------	---------------------	-------------------	--------------------	-----------------------

488 mortality

HIV-positive versus HIV-negative	Hazard	95% CI	P-value
	ratio		
Unadjusted	0.74	0.50-1.09	0.12
Adjusted for sex	0.71	0.48-1.05	0.08
Adjusted for ethnicity	0.77	0.52-1.15	0.21
Adjusted for age	1.39	0.94-2.09	0.10
Adjusted for age and sex	1.39	0.93-2.08	0.11
Adjusted for sex, ethnicity, age, baseline date, and	1.49	0.99-2.25	0.06
indeterminate/probable hospital acquisition of COVID-19			
Adjusted for sex, ethnicity, age, baseline date,	1.49	0.99-2.26	0.06
indeterminate/probable hospital acquisition of COVID-19,			
and 10 comorbidities ^a			
Adjusted for sex, ethnicity, age, baseline date,	1.62	1.06-2.46	0.02
indeterminate/probable hospital acquisition of COVID-19,			
10 comorbidities ^a , and hypoxia at presentation ^b			
Adjusted for sex, ethnicity, age, baseline date,	1.63	1.07-2.48	0.02
indeterminate/probable hospital acquisition of COVID-19,			
10 comorbidities ^a and hypoxia/ receiving oxygen at			
presentation ^b			

^aThe model adjusted for the following comorbidities: chronic cardiac disease, chronic
pulmonary disease, chronic renal disease, diabetes, obesity, chronic neurological disorder,
dementia. liver disease, malignancy, and chronic haematological disease. ^bHypoxia was
defined as SpO2 <94% on air; a record of hypoxia or receiving oxygen at presentation were
used as an indicator of disease severity.

Characteristic		Died n=26		Alive n=89		P-value
Age, median years (IQI	R)	58	(52, 72)	54.5	(49, 60)	0.07
Age group,	<40	1/24	(4.2)	6/89	(6.7)	0.06
n (%)	40-49	4/24	(16.7)	22/89	(24.7)	
	50-59	10/24	(41.7)	37/89	(41.6)	
	60-69	3/24	(12.5)	20/89	(22.5)	
	≥70	6/24	(25.0)	4/89	(4.5)	
ART recorded, n (%)		22/26	(84.6)	83/89	(93.3)	0.17
Type of comorbidities,	Chronic pulmonary disease ^b	0/26	(0)	12/88	(13.6)	0.05
n (%)	Diabetes, with complications	5/26	(19.2)	3/84	(3.6)	0.02
	Obesity	8/24	(33.3)	11/81	(13.6)	0.03
Presenting symptoms,	Cough	22/25	(88.0)	66/89	(74.2)	0.15
n (%)	Diarrhoea	8/22	(36.4)	17/78	(21.8)	0.16
Symptom group, n (%)	Respiratory ^c	24/25	(96.0)	76/89	(85.4)	0.15
Presenting	HR, median beats/min (IQR)	106	(96, 120)	93	(80, 108)	< 0.001
signs	Tachycardia ^d , n (%)	16/25	(64.0)	35/87	(40.2)	0.04
	RR, median breaths/min (IQR)	26	(19, 30)	20	(18, 24)	0.02
	Tachypnoea ^e , n (%)	15/23	(65.2)	35/84	(41.7)	0.05
	Hypoxia ^f /on oxygen, n (%)	18/24	(75.0)	32/84	(38.1)	0.001
	Diastolic BP, median mmHg (IQR)	70	(62, 81)	81	(69, 89)	0.04
	WBC, median count $x10^9/L$ (IQR)	7.8	(5.5, 10.9)	5.7	(4.7, 8.7)	0.02
Laboratory parameters	eGFR ^g , median ml/min/1.73m ² (IQR)	72	(51, 87)	78	(58, 102)	0.12
	Glucose, median mmol/L (IQR)	10.3	(6.4, 12.3)	6.4	(5.8, 8.3)	0.06
	Hyperglycaemia ^h , n (%)	5/13	(38.5)	5/39	(12.8)	0.10
	C-reactive protein, median mg/L (IQR)	203	(103, 306)	92	(42, 149)	< 0.001
Interventions, n (%)	Oxygen therapy during admission	21/26	(80.8)	51/84	(60.7)	0.06
	Critical care admission	17/26	(65.4)	18/89	(20.2)	< 0.001
	Non-invasive ventilation	9/24	(37.5)	15/83	(18.1)	< 0.001
	Invasive ventilation	13/26	(50.0)	6/88	(6.8)	< 0.001

495	Table 5. Characteristics of patients with HIV, stratified by outcome at day 28, selected
496	variables ^a

^aA full list of demographic and clinical characteristics is shown in Supplementary Table 6. ^bExcludes 497 asthma. ^cRespiratory symptoms: ≥ 1 of cough, dyspnoea, chest pain, sore throat, wheeze. ^dDefined as 498 499 HR >100 beats/minute. ^cDefined as RR >20 breaths/min. ^fDefined as SpO2 <94% on air. ^gBased on the Modification of Diet in Renal Disease (MDRD) formula where eGFR (mL/min/1.73 m²) = $175 \times$ 500 501 $(Scr/88.4)-1.154 \times (Age)-0.203 \times (0.742 \text{ if female}) \times (1.212 \text{ if Black ethnicity})$. ^hDefined as glucose 502 >11 mmol/L. Abbreviations: IQR, Interquartile range; ART, Antiretroviral therapy; HR, Heart rate; 503 RR, Respiratory rate; BP, Blood pressure; WBC, White blood cells; eGFR, estimated glomerular 504 filtration rate.

506 LEGENDS TO FIGURES

- 507 **Figure 1.** Flowchart of study participants.
- **Figure 2.** Kernel density plot of age distribution of study participants stratified by HIV status.
- **Figure 3.** Interventions during hospitalisation by HIV status.
- 510 Figure 4. Kaplan Meier survival graphs, stratified by HIV status, sex and age group. P values
- represent log-rank tests. Plots D, E and F include only individuals from age groups <50 years,
- 512 50-59 years and 60-79 years.
- 513

Figure 1. Flowchart of study participants







Figure 2. Kernel density plot of age distribution of study participants stratified by HIV status.



520 **Figure 3.** Interventions during hospitalisation by HIV status.



- 522 Figure 4. Kaplan Meier survival graphs, stratified by HIV status, sex and age group. P values
- represent log-rank tests. Plots D, E and F include only individuals from age groups <50 years,
- 524 50-59 years and 60-79 years.
- 525



526

528 ETHICAL CONSIDERATIONS

529 Ethical approval was given by the South Central - Oxford C Research Ethics Committee in

- 530 England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 20/SS/0028),
- and the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013
- 532

533 DATA AVAILABILITY

The CO-CIN data were collated by ISARIC4C Investigators. ISARIC4C welcomes applications for data and material access through our Independent Data and Material Access Committee (https://isaric4c.net).

537

538 ACKNOWLEDGEMENTS

539 This work uses data provided by patients and collected by the NHS as part of their care and 540 support #DataSavesLives. We are extremely grateful to the 2,648 frontline NHS clinical and 541 research staff and volunteer medical students, who collected the data in challenging circumstances, and the generosity of the participants and their families for their individual 542 543 contributions in these difficult times. We also acknowledge the support of Jeremy J Farrar, 544 Nahoko Shindo, Devika Dixit, Nipunie Rajapakse, Piero Olliaro, Lyndsey Castle, Martha 545 Buckley, Debbie Malden, Katherine Newell, Kwame O'Neill, Emmanuelle Denis, Claire 546 Petersen, Scott Mullaney, Sue MacFarlane, Chris Jones, Nicole Maziere, Katie Bullock, 547 Emily Cass, William Reynolds, Milton Ashworth, Ben Catterall, Louise Cooper, Terry Foster, Paul Matthew Ridley, Anthony Evans, Catherine Hartley, Chris Dunn, Debby Sales, 548 549 Diane Latawiec, Erwan Trochu, Eve Wilcock, Innocent Gerald Asiimwe, Isabel Garcia-550 Dorival, J. Eunice Zhang, Jack Pilgrim, Jane A Armstrong, Jordan J. Clark, Jordan Thomas, 551 Katharine King, Katie Alexandra Ahmed, Krishanthi S Subramaniam, Lauren Lett, Laurence 552 McEvoy, Libby van Tonder, Lucia Alicia Livoti, Nahida S Miah, Rebecca K. Shears, 553 Rebecca Louise Jensen, Rebekah Penrice-Randal, Robyn Kiy, Samantha Leanne Barlow, 554 Shadia Khandaker, Soeren Metelmann, Tessa Prince, Trevor R Jones, Benjamin Brennan, 555 Agnieska Szemiel, Siddharth Bakshi, Daniella Lefteri, Maria Mancini, Julien Martinez, 556 Angela Elliott, Joyce Mitchell, John McLauchlan, Aislynn Taggart, Oslem Dincarslan, 557 Annette Lake, Claire Petersen, and Scott Mullaney.

558

559 FINANCIAL SUPPORT

AS is supported by a National Institute of Health Research (NIHR) Academic Clinical Lectureship at the University of Liverpool. LT is supported by the Wellcome Trust (grant

562 number 205228/Z/16/Z). The work is supported by grants from: the NIHR [award CO-CIN-01]; the Medical Research Council [grant MC_PC_19059]; the NIHR Health Protection 563 564 Research Units (HPRU) in i) Emerging and Zoonotic Infections (NIHR200907) at University 565 of Liverpool in partnership with Public Health England (PHE) and in collaboration with the 566 Liverpool School of Tropical Medicine and the University of Oxford, and ii) Blood Borne 567 and Sexually Transmitted Infections at University College London UCL in partnership with 568 PHE and in collaboration with the London School of Hygiene and Tropical Medicine; the 569 Wellcome Trust and the Department for International Development [215091/Z/18/Z], and the 570 Bill and Melinda Gates Foundation [OPP1209135]. The Liverpool Experimental Cancer 571 Medicine Centre provided infrastructure support for this research (Grant Reference: 572 C18616/A25153). The views expressed are those of the authors and not necessarily those of 573 the DHSC, DID, NIHR, MRC, Wellcome Trust or PHE.

574

575 **DISCLOSURES**

AMG: Personal fees from Roche Pharma Research & Early Development (pRED), consulting 576 577 honoraria from Gilead, Janssen, and ViiV Healthcare, and research funding from Roche 578 pRED, Gilead, Janssen and ViiV Heathcare, outside of the work presented in this article. GV: 579 research funding from ViiV Healthcare outside of the work presented in this article. CAS: 580 personal fees from Gilead Sciences and ViiV Healthcare for participation in Data Safety and 581 Monitoring Boards, membership of Advisory Boards and for preparation of educational materials, outside of the work presented in this article. MGS: grants from DHSC NIHR UK, 582 583 MRC UK, and HPRU in Emerging and Zoonotic Infections during the conduct of the study; 584 other from Integrum Scientific LLC (Greensboro, NC, US), outside the submitted work. The 585 remaining authors declare no competing interests, no financial relationships with any 586 organisations that might have an interest in the submitted work in the previous three years, 587 and no other relationships or activities that could appear to have influenced the submitted 588 work.

590 **References**

- Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital
 with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective
- observational cohort study. BMJ 2020;369:m1985.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
 with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054 1062.
- 597 3. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians.
 598 Clin Microbiol Infect 2020;26:842-847.
- 4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities,
 and outcomes among 5700 patients hospitalized with COVID-19 in the New York City
 area. JAMA 2020;323:2052-2059.
- 5. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and
 immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect.
 2020;S0163-4453:30294-2.
- 605 6. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive
 606 individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS.
 607 2014;28:1193-1202.
- 608 7. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune
 609 dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51-83.
- 8. Ho HE, Peluso MJ, Margus C, et al. Clinical outcomes and immunologic characteristics
 of Covid-19 in people with HIV. J Infect Dis. 2020;jiaa380.
- 9. Del Amo J, Polo R, Moreno S, et al. Incidence and Severity of COVID-19 in HIVPositive Persons Receiving Antiretroviral Therapy: A Cohort Study. Ann Intern Med.
 2020;10.7326/M20-3689.
- 615 10. Waters L, Rockstroh JK. COVID-19 research: an opinion piece. HIV Med.
 616 2020;10.1111/hiv.12913.
- 617 11. De Francesco D, Verboeket SO, Underwood J, et al. Patterns of co-occurring
 618 comorbidities in people living with HIV. Open Forum Infect Dis. 2018;5:ofy272.
- 12. Patel AP, Paranjpe MD, Kathiresan NP, Rivas MA, Khera AV. Race, socioeconomic
 deprivation, and hospitalization for COVID-19 in English participants of a national
 biobank. Int J Equity Health. 2020;19:114.

- 622 13. Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S et al. COVID-19 in
- 623 people living with human immunodeficiency virus: a case series of 33 patients. Infection.
- 624 2020;1-6
- 625 14. Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of HIV patients
 626 with coronavirus disease 2019. Clin Infect Dis. 2020;ciaa579.
- 15. Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case
 series. Lancet HIV. 2020;7:e314-e316.
- 16. Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected
 individuals: a single-centre, prospective cohort. Lancet HIV. 2020;S2352-3018:30164-8.
- 631 17. Childs K, Post FA, Norcross C, et al. Hospitalized patients with COVID-19 and HIV: a
 632 case series.Clin Infect Dis. 2020;ciaa657.
- 18. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19)
 outcomes in HIV/AIDS patients: a systematic review. HIV Med. 2020;10.1111/hiv.1291.
- 19. Mirzaei H, McFarland W, Karamouzian M and Sharifi H. COVID-19 among people
 living with HIV: A systematic review. Preprint. medRxiv.2020;07.11.20151688.
- 637 20. Karmen-Tuohy S, Carlucci PM, Zervou FN, et al. Outcomes among HIV-positive patients
 638 hospitalized with COVID-19. J Acquir Immune Defic Syndr.
 639 2020;10.1097/QAI.00000000002423.
- 640 21. Sigel K, Swartz T, Golden E, et al. Covid-19 and people with HIV infection: Outcomes
 641 for hospitalized patients in New York City. Clin Infect Dis. 2020;ciaa880.
- 642 22. Meyerowitz EA, Kim AY, Ard KL, et al. Disproportionate burden of COVID-19 among
 643 racial minorities and those in congregate settings among a large cohort of people with
 644 HIV. AIDS. 2020;10.1097/QAD.00000000002607.
- 23. Davies MA. HIV and risk of COVID-19 death: a population cohort study from the
 Western Cape Province, South Africa. Preprint. medRxiv. 2020;2020.07.02.20145185
- 647 24. ISARIC4C. ISARIC Coronavirus Clinical Characterisation Consortium. 2020.
 648 <u>https://isaric4c.net/</u>.
- Example 25. Harrison EM, Docherty AB, Barr B, et al. Ethnicity and outcomes from COVID-19: the
 ISARIC CCP-UK prospective observational cohort study of hospitalised patients.
 Preprint. SSRN.2020; 10.2139/ssrn.3618215
- 26. O'Halloran C, Sun S, Nash S, et al. HIV in the United Kingdom: Towards Zero 2030.
 2019 report. London: Public Health England; 2019. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_

- data/file/858559/HIV_in_the_UK_2019_towards_zero_HIV_transmissions_by_2030.pdf.
- 656 Accessed July 30, 2020
- 27. Roghmann MC, Warner J, Mackowiak PA. The relationship between age and fever
 magnitude. Am J Med Sci. 2001;322:68–70.
- 28. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity,
 inflammation and intervention. Nat Rev Immunol. 2020;20:363-374.
- 29. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and
 anticoagulation. Blood. 2020;135:2033-2040.
- 30. Insight START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral
 therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
- 665

666 ISARIC 4C Investigators

- 667 Consortium Lead Investigator: J Kenneth Baillie, Chief Investigator Malcolm G Semple
- 668 Co-Lead Investigator Peter JM Openshaw. ISARIC Clinical Coordinator Gail Carson.

Co-Investigators: Beatrice Alex, Benjamin Bach, Wendy S Barclay, Debby Bogaert, MeeraChand, Graham S Cooke, Annemarie B Docherty, Jake Dunning, Ana da Silva Filipe, Tom

671 Fletcher, Christopher A Green, Ewen M Harrison, Julian A Hiscox, Antonia Ying Wai Ho,

672 Peter W Horby, Samreen Ijaz, Saye Khoo, Paul Klenerman, Andrew Law, Wei Shen Lim,

Alexander, J Mentzer, Laura Merson, Alison M Meynert, Mahdad Noursadeghi, Shona C
Moore, Massimo Palmarini, William A Paxton, Georgios Pollakis, Nicholas Price, Andrew
Rambaut, David L Robertson, Clark D Russell, Vanessa Sancho-Shimizu, Janet T Scott,
Louise Sigfrid, Tom Solomon, Shiranee Sriskandan, David Stuart, Charlotte Summers,

677 Richard S Tedder, Emma C Thomson, Ryan S Thwaites, Lance CW Turtle, Maria Zambon.

678 Project Managers Hayley Hardwick, Chloe Donohue, Jane Ewins, Wilna Oosthuyzen, Fiona

679 Griffiths. Data Analysts: Lisa Norman, Riinu Pius, Tom M Drake, Cameron J Fairfield, 680 Stephen Knight, Kenneth A Mclean, Derek Murphy, Catherine A Shaw. Data and 681 Information System Manager: Jo Dalton, Michelle Girvan, Egle Saviciute, Stephanie Roberts 682 Janet Harrison, Laura Marsh, Marie Connor. Data integration and presentation: Gary 683 Leeming, Andrew Law, Ross Hendry. Material Management: William Greenhalf, Victoria 684 Shaw, Sarah McDonald. Outbreak Laboratory Volunteers: Katie A. Ahmed, Jane A 685 Armstrong, Milton Ashworth, Innocent G Asiimwe, Siddharth Bakshi, Samantha L Barlow, 686 Laura Booth, Benjamin Brennan, Katie Bullock, Benjamin WA Catterall, Jordan J Clark, 687 Emily A Clarke, Sarah Cole, Louise Cooper, Helen Cox, Christopher Davis, Oslem 688 Dincarslan, Chris Dunn, Philip Dyer, Angela Elliott, Anthony Evans, Lewis WS Fisher, Terry

689 Foster, Isabel Garcia-Dorival, William Greenhalf, Philip Gunning, Catherine Hartley, 690 Antonia Ho, Rebecca L Jensen, Christopher B Jones, Trevor R Jones, Shadia Khandaker, 691 Katharine King, Robyn T. Kiy, Chrysa Koukorava, Annette Lake, Suzannah Lant, Diane 692 Latawiec, L Lavelle-Langham, Daniella Lefteri, Lauren Lett, Lucia A Livoti, Maria Mancini, 693 Sarah McDonald, Laurence McEvoy, John McLauchlan, Soeren Metelmann, Nahida S Miah, 694 Joanna Middleton, Joyce Mitchell, Shona C Moore, Ellen G Murphy, Rebekah Penrice-695 Randal, Jack Pilgrim, Tessa Prince, Will Reynolds, P. Matthew Ridley, Debby Sales, Victoria 696 E Shaw, Rebecca K Shears, Benjamin Small, Krishanthi S Subramaniam, Agnieska Szemiel, 697 Aislynn Taggart, Jolanta Tanianis, Jordan Thomas, Erwan Trochu, Libby van Tonder, Eve 698 Wilcock, J. Eunice Zhang. Local Principal Investigators: Kayode Adeniji, Daniel Agranoff, 699 Ken Agwuh, Dhiraj Ail, Ana Alegria, Brian Angus, Abdul Ashish, Dougal Atkinson, 700 Shahedal Bari, Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher Bassford, David 701 Baxter, Michael Beadsworth, Jolanta Bernatoniene, John Berridge, Nicola Best, Pieter 702 Bothma, David Brealey, Robin Brittain-Long, Naomi Bulteel, Tom Burden, Andrew 703 Burtenshaw, Vikki Caruth, David Chadwick, Duncan Chambler, Nigel Chee, Jenny Child, 704 Srikanth Chukkambotla, Tom Clark, Paul Collini, Catherine Cosgrove, Jason Cupitt, Maria-705 Teresa Cutino-Moguel, Paul Dark, Chris Dawson, Samir Dervisevic, Phil Donnison, Sam 706 Douthwaite, Ingrid DuRand, Ahilanadan Dushianthan, Tristan Dyer, Cariad Evans, Chi 707 Eziefula, Chrisopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev Garg, Sanjeev Garg, 708 Atul Garg, Jo Godden, Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn, 709 Daniel Harvey, Peter Havalda, Daniel B Hawcutt, Maria Hobrok, Luke Hodgson, Anita 710 Holme, Anil Hormis, Michael Jacobs, Susan Jain, Paul Jennings, Agilan Kaliappan, Vidya Kasipandian, Stephen Kegg, Michael Kelsey, Jason Kendall, Caroline Kerrison, Ian Kerslake, 711 712 Oliver Koch, Gouri Koduri, George Koshy, Shondipon Laha, Susan Larkin, Tamas Leiner, 713 Patrick Lillie, James Limb, Vanessa Linnett, Jeff Little, Michael MacMahon, Emily 714 MacNaughton, Ravish Mankregod, Huw Masson, Elijah Matovu, Katherine McCullough, 715 Ruth McEwen, Manjula Meda, Gary Mills, Jane Minton, Mariyam Mirfenderesky, Kavya 716 Mohandas, Quen Mok, James Moon, Elinoor Moore, Patrick Morgan, Craig Morris, 717 Katherine Mortimore, Samuel Moses, Mbiye Mpenge, Rohinton Mulla, Michael Murphy, Megan Nagel, Thapas Nagarajan, Mark Nelson, Igor Otahal, Mark Pais, Selva 718 719 Panchatsharam, Hassan Paraiso, Brij Patel, Justin Pepperell, Mark Peters, Mandeep Phull, 720 Stefania Pintus, Jagtur Singh Pooni, Frank Post, David Price, Rachel Prout, Nikolas Rae, 721 Henrik Reschreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, 722 Alistair Rose, Guy Rousseau, Brendan Ryan, Taranprit Saluja, Aarti Shah, Prad Shanmuga,

723 Anil Sharma, Anna Shawcross, Jeremy Sizer, Richard Smith, Catherine Snelson, Nick

724 Spittle, Nikki Staines , Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakmany,

725 Kate Tatham, Jo Thomas, Chris Thompson, Robert Thompson, Ascanio Tridente, Darell

726 Tupper - Carey, Mary Twagira, Andrew Ustianowski, Nick Vallotton, Lisa Vincent-Smith,

727 Shico Visuvanathan, Alan Vuylsteke, Sam Waddy, Rachel Wake, Andrew Walden, Ingeborg

728 Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Meme Wijesinghe, Martin

729 Williams, Lawrence Wilson, Sarah Wilson, Stephen Winchester, Martin Wiselka, Adam

730 Wolverson, Daniel G Wooton, Andrew Workman, Bryan Yates, Peter Young.